Artificial intelligence (AI) is still a controversial topic in some quarters. Fueled by science fiction and often-exaggerated news coverage, some see AI applications s a threat to their job security or way of life. However, AI applications can potentially revolutionize the life science sector regarding efficiency, safety, and innovation – much like insights management technology.
In a recent article for European Pharmaceutical Manufacturer, Jason Smith – Within3’s CTO, AI and analytics – discusses how AI is changing the way pharma companies work, addresses some of the historical reticence around AI adoption, and explores the areas where it can deliver the most value.
While people may be reluctant to incorporate AI tools into their day-to-day in life science settings, these fears are unfounded. The purpose of AI is not to replace humans. In actual fact, it cannot. AI innovation in life science supports and enhances what trial teams and other life science teams can achieve. This can take the form of shortening timelines or simply allowing trial teams to focus on activities other than manual analysis of large data sets.
In the article, Jason examines how life science companies that embrace AI applications will unlock powerful insights they could not have accessed before, thanks to natural language processing and sentiment analysis tools.
The purpose of AI is to ensure important, potentially life-changing insights are not missed. This saves time for life science and healthcare professionals, and adds a degree of confidence to key decisions. For drug and device developers, the reality is that once organizations begin to uncover the benefits of AI, the efficiency of the sector as a whole can only increase.
You can read the article in European Pharmaceutical Manufacturer.
